Article information
Resumen
La esclerosis múltiple (EM) y el lupus eritematoso sistémico (LES) con o sin síndrome antifosfolípido son enfermedades autoinmunes. Se ha descrito en varias ocasiones la asociación de estas enfermedades o se ha descrito el cuadro clínico de la EM con características de laboratorio de LES. Cuando afectan al sistema nervioso central pueden hacerlo en forma definida para cada enfermedad pero también pueden hacerlo en forma interpuesta o combinada de las dos enfermedades, a lo que se le ha llamado esclerosis lupoide, haciendo que en algunos casos sea difícil la diferenciación de las dos enfermedades y por lo tanto direccionar el tratamiento. Presentamos cuatro casos de esclerosis lupoide, discutimos acerca de las características clínicas y de laboratorio de esta entidad y hacemos una diferenciación de la esclerosis múltiple y de la afectación neurológica del LES, especialmente por imágenes y resultados de laboratorio.
Palabras clave:
lupus eritematoso sistémico
esclerosis múltiple
sistema nervioso central
esclerosis lupoide.
Summary
Multiple sclerosis (MS) and Systemic Lupus Erythematosus (SLE) with/without antiphospholipid syndrome are autoinmune illnesses. It has been described in many occasions the association of these two illnesses and the clinical picture of MS with characteristics of laboratory of SLE. When they affect to the central nervous system they can make it in a defined form for each illness or they can also make it in interposed or combined form of the two illnesses what has been called lupoid sclerosis; making that in some cases difficult the differentiation of the two illnesses and therefore to address the treatment. We present four cases of lupoid sclerosis, discuss the clinical and laboratory characteristics of this entity and we make a differentiation of the multiple sclerosis with the neurological affectation of SLE especially for images and laboratory results.
Key words:
systemic lupus erithematosus
sclerosis multiple
central nervous system
lupoid sclerosis.
Full text is only aviable in PDF
Referencias
[1.]
K.W.M. Fulford.
A collagen disorder of nervous system presenting as multiple sclerosis.
Brain, 95 (1972), pp. 373-386
[2.]
E.N. Harris, A.E. Gharavi, C.G. Mackworth-Young, B.M. Patel, G. Derue, G.R.V. Hughes.
Lupoid sclerosis: a possible pathogenic role for antiphospholipid antibodies.
Ann Rheum Dis, 44 (1985), pp. 281-283
[3.]
A. Coles.
Looks like multiple sclerosis, but the ANA is positive: Does my patient have Lupus?.
Practical neurology, (2004), pp. 212-221
[4.]
W. Osler, T. McCrae.
Principles and practices of Medicine.
Ed 10, D Appleton & Co., (1925), pp. 988-990
[5.]
A. Hietaharju, J. Pelttola, J. Seppa, R. Luukkainen, P. Dastidar.
The coexistence of systemic lupus erhytematosus and multiple sclerosis in a mother and daughter.
Scand J Rheumatol, 30 (2001), pp. 120-122
[6.]
F.F. Holmes, D.W. Stubbs, W.E. Larsen.
Systemic lupus erythematosus and multiple sclerosis in identical twins.
Arch Intern Med, 119 (1967), pp. 302-304
[7.]
D.C. Trostle, D. Helfrich, T.A. Medsger Jr..
Systemic sclerosis (scleroderma) and multiple sclerosis.
Arthritis and Rheum, 29 (1986),
[8.]
C. Lucchinetti, W. Bruck, J. Parisi, B. Schethauer, M. Rodríguez, H. Lasssman.
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination.
Ann Neurol, 47 (2000), pp. 707-717
[9.]
F.D. Lubbin, S.C. Reingold.
Defining the clinical course of multiple sclerosis: results of an international survey.
Neurology, 46 (1996), pp. 907-911
[10.]
F.A. Schumacher, G.W. Beeve, R.F. Kibler, et al.
Problems of experimental trials of therapy in multiple sclerosis.
Ann NY Acad Sci, 122 (1965), pp. 552-568
[11.]
C.M. Poser, D.W. Paty, L. Scheinberg, et al.
New diagnostic criteria for multiple sclerosis Guidelines for research protocols.
Ann Neurol, 13 (1983), pp. 227-231
[12.]
W.I. McDonald, A. Compson, G. Edan, et al.
Recommended diagnostic criteria for multiple sclerosis Guidelines from the international panel on the diagnosis of multiple sclerosis.
Ann Neurol, 50 (2001), pp. 121-127
[13.]
F. Jennekens, L. Kater.
The central nervous system in systemic lupus eryhematosus Part. Pathogenic mechanism of clinical syndromes: alterature investigation.
Rheumatology, 41 (2002), pp. 619-630
[14.]
D. Alarcon-Segovia, M. Delize, C.V. Oria, et al.
Antiphospholipid antibodies and antiphospholipid síndrome in systemic lupus erythematosus. A prospective analusis of 5000 consecutive patients.
Medicine, 68 (1989), pp. 353-365
[15.]
N.J. Scolding, F.G. Joseph.
The neuropathology and pathogenesis of systemic lupus erythematosus.
Neuropath Appl Neurobiol, 28 (2002), pp. 173-179
[16.]
N.J. Scolding, W.A. Housten, B.P. Morgan, et al.
Reversible injury of cultured rat oligodendrocytes by complement.
Immunology, 67 (1989), pp. 441-446
[17.]
A. Tourbah, A. Clapin, O. Gout, et al.
Systemic autoimmune features and multiple sclerosis- a 5 year follow up study.
Arch Neurol, 55 (1998), pp. 517-521
[18.]
D. Karussis, R.R. Leker, A. Ashkenazi, O. Abramsky.
A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do the represent a new nosological enty?.
Ann Neurol, 44 (1998), pp. 629-634
[19.]
S. Marullo, J.P. Claufvel, L. Intrato, F. Danon, J.C. Brouet, E. Oksenhendler.
Lupoid sclerosis with antiphospholipid and antimyelin antibodies.
J Rheumatol, 20 (1993), pp. 747-749
[20.]
A. Robos, Ecvangeloupulou-Katsiri, A. Leventakou, K. Voumvourakis, N. Trintafyllou, C. Papageourgiou.
Serum IgG and IgM anticardiolipin antibodies in neurological diseases.
Acta Neurol Scand, 81 (1990), pp. 43-45
[21.]
Report of the therapeutics and technology assesssment Subcommitee of the American Academy of neurology. The utility of MRI in suspected MS. Neurology 2003; 61(5).
[22.]
K.W.M. Fulford, R.D. Catteral, J.J. delhanty, D. Doniach, M. Kremer.
A collagen disorder of nervous system presenting as multiple sclerosis.
Brain, 95 (1972), pp. 368-373
[23.]
A. Iglesias Gamarra.
Manifestaciones neurológicas del lupus.
Historia del Lupus, Editorial Panamericana, (2003),
[24.]
W.J. McKune, J. Golbus.
Neuropsychiatric Lupus.
Rheum Dis Clin North Am, 14 (1998), pp. 149-167
[25.]
J.W. Ijdo, A.M. Conti Nelly, P. Greco, M. Abedi, M. Amorg, J.M. Provenzale, T.P. Greco.
Antiphospholipid antibodies in patients with multiple sclerosis and MSlike disese illness: MS or APS?.
Lupus, 8 (1999), pp. 109-115
[26.]
A. Tourbach, A. Clapin, O. Gout, B. Fountain, R. Liblan, F. Batteux, J.L. Stievenart, Weill B.F Lyon-Caen..
Systemic aotommune features and multiple sclerosis: A 5-year follw-up Study.
Arch Neurol, 55 (1998), pp. 517-521
[27.]
M.J. Cuadrado, A. Khamashta, T. Ballesteros, T. Godfrey, M.J. Simon, Hughes.
GRV can neurological manifestations of Hughes (antiphospholipid) syndrome be distinguished from Multiple Sclerosis?.
Medicine, (2000), pp. 57-68
[28.]
Hietaharju Aki, Pelttola Jukka, Seppa Juha, Luukkainen Reijo, Dastidar Prasun.
The coexistence of systemic lupus erhytematosus and multiple sclerosis in a mother and daughter.
Scand J Rheumatol, 30 (2001), pp. 120-122
[29.]
Sabbadini MG, Manfredi AA, Bozzolo E, et al. Central nervous system involvement in Sytemic lupus Erythematosus patients without overt neuropsychitric manifestations. Lupus 8:11-19.
[30.]
Tellez-Zenteno JF, Remes-Troche JM, Negret Pulido RO. Longitudinal myelitis associated with systemic lupus erythematosus: clicical features and magnetic resonante imaging of six cases. Lupus 10:851-856.
[31.]
F. Barkhof, M. Filippi, D.H. Miller, et al.
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Brain, 120 (1997), pp. 2059-2069
[32.]
Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 58(suppl4):S23-S31.
[33.]
E. Hachulla, U. Michon-Pasurel, D. Leys, et al.
Cerebral MRI in patients with or without antiphospholipid antibodies.
Lupus, 7 (1998), pp. 124-131
[34.]
E. Trysberg, A. Tarkowski.
Cerebral inflammation and degeneration in systemic lupus eythematosus.
Curr Opin Rheumatol, 16 (2004), pp. 527-533
[35.]
S. Barred, A. Goodman, D. Mattson.
Frequency of anti-nuclear antibodies in multiple sclerosis.
Neurology, 45 (1995), pp. 384-385
[37.]
M.A. Cordoliani, U. Michon-Pasturel, K. Rerar, et al.
Multiple sclerosis and antiphospholipid antibodies: study of 62 cosecutive patients.
Review Medical Interne, 19 (1998), pp. 635-639
[38.]
O. Heinslef, B. Weill, C. Johanet, et al.
Anticardiolipin antibodies in patients of multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics.
Journal of neurology, neurosurgery and psychiatry, 72 (2002), pp. 647-649
[39.]
V. Roussel, F. Yi, M.O. Jauberteau, et al.
Preud’homme. J. I. Prevalence and clinical significance of antiphospholipid antibodies in multiple sclerosis: a study of 89 patients.
Journal of autoimmune, 14 (2002), pp. 259-265
[40.]
S. Ferreira, D.P. DCruz, G.R.V. Hughes.
Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: Where do we stand?.
Rheumatology, (2005),
[41.]
T.F. Scott, D. Hess, J. Brillman.
Antiphospholipid antibody syndrome mimicking multiple sclerosis both clinically and by magnetic resonance imaging.
Arch Intern Med, 154 (1994), pp. 917-920
[42.]
D. DCruz, S. Mellor-Pita, B. Joven, et al.
Transverse myelitis as first manifestations of systemic lupus erythematosus of lupus-like disease: good fuctional outcome and relevance of antiphospholipid antibodies.
J Rheumatol, 31 (2004), pp. 280-285
[43.]
A. Aziz, M.D. Conway, H.J. Robertson, L.R. Espinosa, W.A. Wilson.
Acute optic neuropathy and transverse myelitis in patients with antiphospholipid syndrome: favorable outcome after treatment with anticoagulants and glucocorticoides.
Lupus, 9 (2000), pp. 307-310
[44.]
B. Kovacs, T.L. Lafferty, H. Lawrence, R.J. DeHoratius.
Transverse mielopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature.
Ann Rheum Dis, 59 (2005), pp. 120-124
[45.]
D. Giorgio, C.B. Grabieki.
Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome: clinical features, pathogenesis, review of the literature and proposed ophtalmological driteria for APS diagnosis.
Clin Rheumatol, 18 (1999), pp. 124-131
[46.]
J.H. Noseworthy, C. Luchinetti, M. Rodriguez, B.G. Wenshenker.
Multiple sclerosis.
N Eng J Med, 343 (2000), pp. 938-952
[47.]
G. Sanna, M.L. Bertolaccini, M.J. Cuadrado, et al.
Neuropsychyatric manifestations in systemic lupus erythematosus: prevalence and associations with antiphospholipid antibodies.
J Rheumatol, 30 (2003), pp. 985-992
[48.]
N. Scolding.
Neurological complications of rheumatological and connective tissue disorders.
Immunological and inflammatory disorders of the central nervous system, 1st edn. (ed. Scolding N), Butterworth-Heinemann, (1999), pp. 147-180
[49.]
K. Baracza, K. Nekam, T. Pozsonyi, et al.
Investigation of cytokine (tumor necrosis factor-alfa, inerleukin-6, interleukin-10) concentracions in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus.
European Journal of Neurology, 11 (2004), pp. 37-42
[50.]
K. Baraczka, G. Lakos, S. Sipka.
Immuoserological changes in the cerebrospinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis.
Acta Neurol Scand, 105 (2002), pp. 378-383
[51.]
R.T. Johnsosn, E.P. Richardson.
The neurological manifestations of systemic lupus erythematosus.
Medicine, 47 (1968), pp. 337-369
[52.]
J.G. Hanly, N.M. Wals, V. Sangalang.
Brain Pathology in systemic lupus erythematosus.
J Rheumatol, 19 (1992), pp. 732-741
[53.]
H.M. Belmont, S.B. Abramson, J.T. Lie.
Pathology and pathogenesis of vascular injury in systemic lupus erythematosus Interactions of inflammatory cells and activated endothelium.
Arthritis Rheum, 39 (1996), pp. 9-22
[54.]
S. Oppenheimer, B.I. Hoffbrand.
Optic neuritis and myelopathy in systemic lupus erythematosus.
Can J Neurol Sci, 13 (1986), pp. 129-132
[55.]
M.K. Crow.
Interferon-á: a new target for therapy in systemic lupus erythematosus?.
Arthritis Rheum, 48 (2003), pp. 2396-2401
Copyright © 2010. Asociación Colombiana de Reumatología
